From: Clinical significance of focal ß-amyloid deposition measured by 18F-flutemetamol PET
No-FMM uptake (n = 174) | Focal-FMM uptake (n = 53) | Diffuse-FMM uptake (n = 83) | p No vs focal uptake | p No vs diffuse uptake | p Focal vs diffuse uptake | |
---|---|---|---|---|---|---|
Age (mean ± SD) | 69.4 ± 8.6 | 73.5 ± 7.9 | 71.4 ± 8.5 | 0.008 | 0.253 | 0.494 |
Men (%) | 73 (42.0) | 15 (28.3) | 37 (44.6) | 0.075 | 0.692 | 0.058 |
Education, years (mean ± SD) | 10.7 ± 5.0 | 10.3 ± 5.0 | 11.0 ± 4.5 | 1.000 | 1.000 | 1.000 |
APOE ε4 carrier (%) | 21/166 (12.7) | 23/53 (43.4) | 42/81 (51.9) | < 0.001 | < 0.001 | 0.340 |
Disease duration (months) (Mean ± SD) | 62.5 ± 52.9 | 50.3 ± 44.5 | 41.5 ± 41.6 | 0.455 | 0.009 | 1.000 |
Vascular risk factors | ||||||
Hypertension (%) | 80 (46.0) | 23 (43.4) | 29 (34.9) | 0.742 | 0.095 | 0.324 |
Diabetes (%) | 33 (19.0) | 5 (9.4) | 11 (13.3) | 0.104 | 0.257 | 0.502 |
Hyperlipidemia (%) | 57 (32.8) | 18 (34.0) | 11 (13.3) | 0.871 | 0.001 | 0.004 |
Cognitive level | < 0.001 | < 0.001 | < 0.001 | |||
CU (%) | 102 (58.6) | 17 (32.1) | 6 (7.2) | |||
MCI (%) | 64 (36.8) | 20 (37.7) | 41 (49.4) | |||
ADD (%) | 8 (4.6) | 16 (30.2) | 36 (43.4) |